Physician profile
Robert D Footer
NPI 1376562116
$635.85
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $132 · 2021: $116 · 2022: $250.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.96 | 2019-2022 | |
| Avion Pharmaceuticals | $85.24 | 2020-2022 | |
| Pfizer INC. | $70.30 | 2019-2021 | |
| Myovant Sciences INC. | $68.86 | 2022 | |
| Therapeuticsmd, INC. | $59.23 | 2019-2020 | |
| Evofem Biosciences, INC. | $29.68 | 2021-2022 | |
| Aspira Women'S Health INC | $24.76 | 2022 | |
| Organon LLC | $24.72 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $21.13 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.34 | 2020 | |
| Merck Sharp & Dohme LLC | $19.10 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.02 | 2019 | |
| Exeltis, USA INC. | $15.17 | 2021 | |
| Mission Pharmacal Company | $12.44 | 2019 | |
| Coopersurgical, INC. | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Footer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.